Kaletra kan øge koncentrationerne af lægemidler, der anvendes samtidig, og dette kan resultere i en stigning i disses relaterede kardiale bivirkninger.
Indeed, Kaletra could increase concentrations of the co-administered medicinal products and this may result in an increase of their associated cardiac adverse events.